BRAF testing and targeted treatment in BRAF-mutated melanoma patients is not standard of care in all countries and all clinical practices, and understanding the total-cost economics and health value produced from this treatment strategy may be valuable in guiding future standards. This evidence concerns the gene BRAF and melanoma.